Brief: Tempest Lays Out Strategic Plan To Advance Recently Acquired Dual-Targeting Car-T Assets
11/02/2026 12:00
Feb 11 (Reuters) - Tempest Therapeutics Inc TPST.O: TEMPEST LAYS OUT STRATEGIC PLAN TO ADVANCE RECENTLY ACQUIRED DUAL-TARGETING CAR-T ASSETS TEMPEST THERAPEUTICS INC - PRIORITIZES TPST-2003 AND EXPANDS WITH TPST-4003 TEMPEST THERAPEUTICS INC - EXPECTS PHASE 2B INITIATION FOR TPST-2003 BY 2026 IN CHINA TEMPEST THERAPEUTICS INC - TO INITIATE PHASE 2 STUDY OF TPST-1495 IN Q1 2026 TEMPEST THERAPEUTICS INC - PLANS TO PROGRESS ADDITIONAL DUAL TARGETING TPST-3003 CAR-T PROGRAM Source text: ID:nGNX8ry0RW Further company coverage: TPST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T